gnc-038

mAbexperimentalQuad-specific

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06857227Phase 1Mar 31, 2025Baili Pharmaceutical Group
NCT06857214Phase 1Mar 31, 2025Baili Pharmaceutical Group
NCT05623982Phase 1/Phase 2 (Phase 2)Dec 31, 2022Baili Pharmaceutical Group, Peking University, SystImmune Inc.
NCT05627856Phase 1/Phase 2 (Phase 2)Nov 30, 2022Baili Pharmaceutical Group, Shantou University, Sun Yat-Sen University, SystImmune Inc.
NCT05485753Phase 1/Phase 2 (Phase 2)Feb 14, 2022Baili Pharmaceutical Group, Capital Medical University, SystImmune Inc.
NCT05192486Phase 1/Phase 2 (Phase 2)Dec 14, 2021Baili Pharmaceutical Group, Jiao Tong University, SystImmune Inc.
NCT04606433Phase 1Nov 30, 2020Baili Pharmaceutical Group, Chinese Academy of Medical Sciences, SystImmune Inc.
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Baili Pharmaceutical GroupFor profit7722020
SystImmune Inc.For profit5022020
Capital Medical UniversityAcademic/Hospital1012022
Chinese Academy of Medical SciencesAcademic/Hospital1012020
Jiao Tong UniversityAcademic/Hospital1012021
Peking UniversityAcademic/Hospital1012022
Shantou UniversityAcademic/Hospital1012022
Sun Yat-Sen UniversityAcademic/Hospital1012022
8 organizations
Page 1 / 1